Treat 503A and 503B as distinct legal frameworks, not supplier quality tiers or interchangeable routes to lower prices.
| Question | Section 503A | Section 503B |
|---|---|---|
| Patient-specific prescription? | Generally centres on an identified individual patient and a valid prescription, with conditions governing limited anticipatory compounding | An outsourcing facility may or may not obtain prescriptions for identified individual patients |
| General office stock? | A patient-specific prescription route should not be presented as general office-stock permission | Can support qualifying office-stock arrangements, subject to all applicable conditions |
| Manufacturing standard? | Qualifying products are exempt from federal current good manufacturing practice requirements; that does not remove other quality obligations | Not exempt from current good manufacturing practice requirements |
| Copying restriction? | Restrictions on regularly or inordinately compounding essentially copies of commercially available products | Separate restriction on preparations that are essentially copies of approved drugs |
| Raw-ingredient question? | Assess the applicable bulk-substance conditions and exact ingredient | Bulk-substance eligibility is an independent gate; a prescription does not remove it |
| Buyer evidence? | Prescription process, actual formulation, relevant prescriber determination and pharmacy quality evidence | Exact facility, registration and inspection history, preparation-specific basis, quality systems and supply chain |
These distinctions are supported by FDA's framework and the 503B statute. Neither route produces an FDA-approved compounded medicine. (fda.gov)
Does a patient-specific prescription or added B12 make compounding permissible?
Neither is an automatic exemption. FDA's 503A guidance explains that a prescriber determination must identify a formulation change producing a significant difference for the individual patient; merely identifying the patient and formulation is insufficient for that determination. Lower price alone is not sufficient. (fda.gov)
FDA's semaglutide with vitamin B12 can still meet its essentially-copy criteria. A supplier's standard additive should therefore trigger questions, not close the legal review. (fda.gov)
For a proposed exception, request:
- The exact active ingredient, formulation, concentration, dosage form and source.
- The applicable statutory pathway and product-specific legal analysis.
- The clinician's independent assessment and documentation where relevant.
- The compounding and dispensing facilities—not just the marketing company.
- Quality, labelling, beyond-use and post-opening instructions.
- Destination-state permissions and a transition plan if the arrangement stops.
FDA identifies semaglutide sodium and semaglutide acetate as different active ingredients from that used in approved products and says it is unaware of a lawful basis for their use in compounding. Do not accept a generic statement that the ingredient is simply semaglutide. (fda.gov)
Can a broker resell 503B products to a clinic?
Do not assume an ordinary wholesale resale model is permissible. Section 503B includes a prohibition on sale or transfer by an entity other than the outsourcing facility that compounded the drug, with specified treatment-setting administration and prescription-dispensing provisions. Have counsel map the actual title, payment and transfer chain. (govinfo.gov)
Explore the table row by row
A working view of the research
Patient-specific prescription?
- Section 503A
- Generally centres on an identified individual patient and a valid prescription, with conditions governing limited anticipatory compounding
- Section 503B
- An outsourcing facility may or may not obtain prescriptions for identified individual patients
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/media/162166/download?utm_source=openai
- fda.gov · Source 2 ↗https://www.fda.gov/media/98973/download?attachment=&os=apprefDapp
- fda.gov · Source 3 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- fda.gov · Source 4 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss?ftag=YHF4eb9d17
- govinfo.gov · Source 5 ↗https://www.govinfo.gov/content/pkg/USCODE-2024-title21/html/USCODE-2024-title21-chap9-subchapV-partA-sec353b.htm